ServiceTitan initiated, Viracta downgraded: Wall Street's top analyst calls [Yahoo! Finance]
Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its "neutral" rating re-affirmed by analysts at Rodman & Renshaw. They now have a $0.25 price target on the stock, down previously from $3.50.
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives [Yahoo! Finance]
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives
Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its price target lowered by analysts at Royal Bank of Canada from $4.00 to $2.00. They now have an "outperform" rating on the stock.